CD40标靶治疗的全球市场:临床试验，治疗方法，市场机会的洞察(2025年)

CD40标靶治疗已成为免疫治疗研究的热点，人们对利用CD40受体的潜力治疗多种疾病越来​​越感兴趣。儘管 CD40 标靶疗法尚未批准用于临床，但几种有希望的候选疗法目前正处于后期临床开发阶段。此外，预计更多候选药物将在明年进入后期临床试验，从而扩大临床开发中的 CD40 标靶疗法库。这些正在进行的研究和临床试验表明，CD40标靶治疗可能成为未来几年患病人群的重要治疗选择。

从历史上看，CD40标靶治疗的主要焦点是自体免疫疾病和发炎性疾病。然而，人们对探索 CD40 标靶疗法治疗癌症和其他疾病的潜力越来越感兴趣。最近的研究扩大了 CD40 的治疗范围，包括 HIV 和 COVID-19 等传染病，以及阿兹海默症和帕金森氏症等神经退化性疾病。此外，研究表明，CD40标靶治疗可能对CD40讯号传导路径不直接参与疾病发作的疾病有效，例如涉及疾病进展和发炎的心血管疾病。

独特技术和平台的出现极大地促进了 CD40 标靶疗法的发展。一个着名的例子是 GenMab 的 DuoBody 平台，该平台能够创建同时针对两种不同抗原的双特异性抗体。该技术已被用于开发几种有前途的免疫疗法，包括目前处于恶性实体瘤二期试验的 CD40 标靶疗法 GEN1042/BNT312。

总而言之，CD40 标靶疗法尚未被批准用于临床，但在多种疾病中是一个有前途且快速发展的研究和开发领域。随着越来越多的治疗方法进入临床试验以及竞争格局的加剧，CD40 标靶疗法可能很快就会成为癌症、自体免疫疾病、传染病等疾病治疗的基石。

本报告提供全球CD40标靶治疗市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，及加入此市场的主要企业竞争情形等资讯。

目录

第1章 CD40标靶治疗的简介

第2章 CD40标靶治疗- 作用机制

第3章 把CD40作为标的治疗方法

• 抗体的形式
• 融合蛋白品质
• [月太]
• 核酸

第4章 CD40标靶治疗的研究开发趋势，各适应症

• 癌症
• 神经疾病
• 自体免疫疾病及发炎性疾病
• 移植排斥反应
• 微生物感染疾病

第5章 全球CD40标靶治疗市场预测

• 目前市场趋势和趋势
• 未来市场机会

第6章 CD40标靶治疗市场趋势分析，各地区

• 美国
• 欧洲
• 中国
• 日本
• 澳洲

第7章 CD40标靶治疗的临床试验相关企业，国家，适应症，各相的考察

• 调查
• 前临床
• 第一阶段
• 第一/二阶段
• 第二阶段
• 第三阶段

第8章 CD40标靶治疗- 各企业专利技术

第9章 全球CD40标靶治疗市场动态

• 促进因素和机会
• 课题与阻碍因素

第10章 竞争情形

• Alligator Bioscience
• Amgen
• Biogen
• BioNTech
• Eledon Pharmaceuticals
• EnnoDC
• Genmab
• Innovent Bio
• Novartis
• Sanofi
• Tonix Pharmaceuticals
• UCB

Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025 Report Highlights:

• First CD40 Targeted Therapy Approval Expected By 2027
• CD40 Targeted Therapies In Clinical Trials: > 20 Therapies
• CD40 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
• CD40 Targeted Therapy Research & Development Trends By Indication
• CD40 Targeted Therapy Market Trend Analysis By Region
• CD40 Targeted Therapies Proprietary Technologies By Company

CD40 targeted therapies have become a focal point in immunotherapy research, with growing attention on harnessing the potential of the CD40 receptor to treat a variety of diseases. While no CD40 targeted therapies have yet been approved for clinical use, some promising candidates are currently undergoing late stage clinical development. Moreover, additional candidates are slated to enter late-stage trials within the next year, expanding the pool of CD40 targeted therapies in clinical development. These ongoing research and clinical trials suggest that CD40 targeted therapies could become a vital treatment option for patients with prevalent diseases in the coming years.

Historically, the primary focus of CD40 targeted therapies has been on autoimmune and inflammatory diseases. However, there is an increasing interest in exploring their potential for treating cancer and other conditions. More recent studies have expanded the scope of CD40 targeting to include infectious diseases, such as HIV and COVID-19, as well as neurodegenerative diseases like Alzheimer's and Parkinson's disease. Some research has also suggested that CD40 targeted therapies might be beneficial for diseases like cardiovascular conditions, where CD40's signaling pathway, although not directly involved in disease initiation, plays a role in disease progression and inflammation.

Over the years, various strategies have been employed to target the CD40 receptor and its ligand. These include traditional monoclonal antibodies as well as next-generation molecular therapeutics such as small interfering RNA (siRNA). While antibodies are developed either as CD40 agonists or as antagonists, CD40 targeted siRNAs aim to reduce CD40 protein expression by degrading CD40 mRNA. Several other conventional and next-generation approaches are undergoing active research and clinical trials to assess their safety and efficacy.

Nonetheless, antibody therapies remain the dominant approach in CD40 targeted research. Among the most advanced CD40/CD40L targeted antibodies are those for autoimmune and inflammatory diseases, with some entering phase 3 clinical trials. For example, Sanofi's Frexalimab, a promising anti CD40 antibody, is currently in phase 3 trials for autoimmune conditions. In the cancer domain, CD40 targeted antibodies are also making significant strides, with companies like Alligator Bioscience preparing to initiate phase 3 clinical trials for its lead candidate, mitazalimab, an anti-CD40 antibody for pancreatic ductal adenocarcinoma (PDA) and pancreatic cancer.

The development of CD40 targeted therapies has been greatly facilitated by the advent of proprietary technologies and platforms. One notable example is GenMab's DuoBody platform, which enables the creation of bispecific antibodies that can target two different antigens simultaneously. This technology has been leveraged to develop several promising immunotherapies, including its CD40 targeted therapy, GEN1042/BNT312, currently in phase 2 trial for malignant solid tumors.

As the field of CD40 targeted therapies evolves, the competitive landscape is becoming increasingly crowded, with many major pharmaceutical companies entering the arena. Notable players include Amgen, Sanofi, GenMab, BioNTech, and Biogen, all of which are investing heavily in this space. Collaborations between pharmaceutical companies and academic institutions have been essential in advancing the scientific understanding of CD40 targeted therapies, combining cutting edge research with clinical expertise to bring these therapies closer to market.

In conclusion, while CD40 targeted therapies have not yet been approved for clinical use, they represent a promising and rapidly developing area of research across a wide range of diseases. As more therapies enter clinical trials and the competitive landscape intensifies, it is clear that CD40 targeted therapies could become a cornerstone of treatment for cancer, autoimmune diseases, infectious diseases, and beyond in the near future.

Table of Contents

1. Introduction To CD40 Targeted Therapies

• 1.1 Overview
• 1.2 Considering CD40 As Drug Target Over Other CD Markers
• 1.3 History & Evolution Of CD40 Targeting Therapies

2. CD40 Targeted Therapies - Mechanism Of Action

• 2.1 Agonist Mediated Activation Of CD40 Signaling
• 2.2 Antagonist-Mediated Inhibition Of CD40 Signaling

3. CD40 Targeted Therapeutic Approaches

• 3.1 Antibody Formats
• 3.2 Fusion Proteins
• 3.3 Peptides
• 3.4 Nucleic Acids

4. CD40 Targeted Therapy Research & Development Trends By Indication

• 4.1 Cancer
• 4.2 Neurological Diseases
• 4.3 Autoimmune & Inflammatory Disorders
• 4.4 Transplant Rejection
• 4.5 Microbial Infections

5. Global CD40 Targeted Therapy Market Outlook

• 5.1 Current Market Trends & Developments
• 5.2 Future Market Opportunities

6. CD40 Targeted Therapy Market Trend Analysis By Region

• 6.1 US
• 6.2 Europe
• 6.3 China
• 6.4 Japan
• 6.5 Australia

7. CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

• 7.1 Research
• 7.2 Preclinical
• 7.3 Phase I
• 7.4 Phase I/II
• 7.5 Phase II
• 7.6 Phase III

8. CD40 Targeted Therapies - Proprietary Technologies By Company

• 8.1 Alligator Bioscience - FIND Technology & Neo-X-Prime
• 8.2 Aprilbio - SAFA Platform
• 8.3 Biocytogen - RenMice
• 8.4 EnnoDC - Unnamed Platform
• 8.5 Genmab - DuoBody
• 8.6 Harbour BioMed - Harbour Mice & HBICE
• 8.7 Kyowa Kirin - REGULGENT
• 8.8 Strike Pharma - ADAC Technology Platform

9. Global CD40 Targeted Therapy Market Dynamics

• 9.1 Drivers & Opportunities
• 9.2 Challenges & Restraints

10. Competitive Landscape

• 10.1 Alligator Bioscience
• 10.2 Amgen
• 10.3 Biogen
• 10.4 BioNTech
• 10.5 Eledon Pharmaceuticals
• 10.6 EnnoDC
• 10.7 Genmab
• 10.8 Innovent Bio
• 10.9 Novartis
• 10.10 Sanofi
• 10.11 Tonix Pharmaceuticals
• 10.12 UCB

List of Figures

• Figure 1-1: CD40 - Salient Features
• Figure 1-2: CD40 Targeted Therapy Landscape - Major Milestones
• Figure 2-1: CD40 Agonists - Mechanism of Action
• Figure 3-1: Prominent Antibody Formats for Targeting CD40
• Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study - Initiation & Completion Year
• Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study - Initiation & Completion Year
• Figure 4-3: 2141-V11 Phase 1/2 (NCT05126472) Study - Initiation & Completion Year
• Figure 4-4: 2141-V11 Phase 1 (NCT06455605) Study - Initiation & Completion Year
• Figure 4-5: 2141-V11 Phase 1/2 (NCT05734560) Study - Initiation & Completion Year
• Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study - Initiation & Completion Year
• Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study - Initiation & Completion Year
• Figure 4-8: FREXALT 3 (NCT06141473) Study - Initiation & Completion Year
• Figure 4-9: HZNP-DAZ-301 Phase 3 (NCT06104124) Study - Initiation & Completion Year
• Figure 4-10: HZNP-DAZ-303 Phase 3 (NCT06245408) Study - Initiation & Completion Year
• Figure 4-11: VIBRANT Phase 2 (NCT05201469) Study - Initiation & Completion Year
• Figure 4-12: CONTROL-RA Phase 2 (NCT05306353) Study - Initiation & Completion Year
• Figure 4-13: PHOENYCS FLY Phase 3 (NCT06617325) Study - Initiation & Completion Year
• Figure 4-14: SL0046 Phase 3 (NCT04976322) Study - Initiation & Completion Year
• Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study - Initiation & Completion Year
• Figure 4-16: FABULINUS Phase 2 (NCT06111586) Study - Initiation & Completion Year
• Figure 4-17: IRB23-1367 Phase 1/2 (NCT06111586) Study - Initiation & Completion Year
• Figure 4-18: AT-1501-K102 Phase 1 (NCT05027906) Study - Initiation & Completion Year
• Figure 4-19: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study - Initiation & Completion Year
• Figure 4-20: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study - Initiation & Completion Year
• Figure 4-21: ANRS VRI06 Phase 1 (NCT04842682) Study - Initiation & Completion Year
• Figure 4-22: HVTN 318 Phase 1 (NCT06665646) Study - Initiation & Completion Year
• Figure 4-23: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study - Initiation & Completion Year
• Figure 8-1: Alligator Bioscience - FIND technology
• Figure 8-2: Alligator Bioscience - Neo-X-Prime
• Figure 8-3: Aprilbio - SAFA Antibody APB-A1
• Figure 8-4: Genmab - DuoBody
• Figure 8-5: Harbour BioMed - Harbour Mice
• Figure 8-6: Harbour BioMed - HCAb
• Figure 8-7: H2L2 & HCAb Platforms - Features
• Figure 8-8: Harbour BioMed - HBICE
• Figure 8-9: Kyowa Kirin - REGULGENT
• Figure 8-10: ADAC Technology Platform - Features

Figure 8-11 Strike Pharma - ADAC Technology Platform

• Figure 8-12: Strike Pharma - ADAC Molecule
• Figure 9-1: CD40 Targeted Therapy Market - Drivers & Opportunities
• Figure 9-2: CD40 Targeted Therapy Market - Challenges & Restraints

List of Tables

• Table 5-1: CD40 Targeted Therapies in Phase III Clinical Trials
• Table 7-1: CD40 Targeted Therapies in Research Stage, 2024
• Table 7-2: CD40 Targeted Therapies in Preclinical Stage, 2024
• Table 7-3: CD40 Targeted Therapies in Phase I, 2024
• Table 7-4: CD40 Targeted Therapies in Phase I/II, 2024
• Table 7-5: CD40 Targeted Therapies in Phase II, 2024
• Table 7-6: CD40 Targeted Therapies in Phase III, 2024